Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation – summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019

Concerning development of medicinal products, children belong to a so-called “special population” for which additional legislation applies: Regulation (EC) No 1901/2006 on medicinal products for paediatric use sets up a system of requirements, rewards and incentives to ensure that medicinal products...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahler, V., Mentzer, D., Bonertz, A., Muraro, A., Eigenmann, P., Bousquet, J., Halken, S., Pfaar, O., Jutel, M., Wahn, U., Vieths, S., Kaul, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325268/
https://www.ncbi.nlm.nih.gov/pubmed/32612805
http://dx.doi.org/10.1186/s13601-020-00327-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325268/
https://www.ncbi.nlm.nih.gov/pubmed/32612805
http://dx.doi.org/10.1186/s13601-020-00327-w

Ejemplares similares